p185neu expression in human lung adenocarcinomas predicts shortened survival.
about
ErbB-2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancerMolecular understanding of lung cancers-A review.Differential binding patterns of monoclonal antibody 2C4 to the ErbB3-p185her2/neu and the EGFR-p185her2/neu complexes.Antiproliferative and apoptotic activities of ketonucleosides and keto-C-glycosides against non-small-cell lung cancer cells with intrinsic drug resistance.Engagement of overexpressed Her2 with GEP100 induces autonomous invasive activities and provides a biomarker for metastases of lung adenocarcinoma.Cell-type specific interaction of Neu differentiation factor (NDF/heregulin) with Neu/HER-2 suggests complex ligand-receptor relationshipsC-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas.Plasmid DNA delivery into MDA-MB-453 cells mediated by recombinant Her-NLS fusion protein.Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivoThe role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literatureRole of extracellular subdomains of p185c-neu and the epidermal growth factor receptor in ligand-independent association and transactivationNeu proto-oncogene amplification and expression in ovarian adenocarcinoma cell linesIn vitro and in vivo expressions of transforming growth factor-alpha and tyrosine kinase receptors in human non-small-cell lung carcinomas.The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survivalPrediction of recurrence by quantification of p185neu protein in non-small-cell lung cancer tissuePeptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyLack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections.Tyrosine phosphorylation of 100-130 kDa proteins in lung cancer correlates with poor prognosis.Laminin activates the p185HER2 oncoprotein and mediates growth inhibition of breast carcinoma cellsAn activated allele of the c-erbB-2 oncogene impairs kidney and lung function and causes early death of transgenic mice.New perspectives in lung cancer. 2. Growth factors and lung cancer.The role of transforming growth factor alpha production and ErbB-2 overexpression in induction of tumorigenicity of lung epithelial cellsOverexpression of HER-2 in MDA-MB-435/LCC6 Tumours is Associated with Higher Metabolic Activity and Lower Energy Stress.Inverse regulation of human ERBB2 and epidermal growth factor receptors by tumor necrosis factor alpha.Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma.Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancerMultiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancerEvaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomasPhosphorylated tyrosine-containing proteins in primary lung cancer correlates with proliferation and prognosis.p185c-neu and epidermal growth factor receptor associate into a structure composed of activated kinasesCharacterization of a growth factor that binds exclusively to the erbB-2 receptor and induces cellular responses.Structure based antibody-like peptidomimetics.The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.Interaction of cytokeratin 19 head domain and HER2 in the cytoplasm leads to activation of HER2-Erk pathway.HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patientsCharacterization of a neu/c-erbB-2 protein-specific activating factorActive targeting using HER-2-affibody-conjugated nanoparticles enabled sensitive and specific imaging of orthotopic HER-2 positive ovarian tumors.The challenge to bring personalized cancer medicine from clinical trials into routine clinical practice: the case of the Institut Gustave Roussy.Repair of triplex-directed DNA alkylation by nucleotide excision repair.When Good Turns Bad: Regulation of Invasion and Metastasis by ErbB2 Receptor Tyrosine Kinase.
P2860
Q28678776-624B7050-78C9-43D2-985E-F36EF5F92EE6Q33628898-E9F9C140-65CD-427C-90BC-A13931047342Q33642507-20C4D767-70A2-4A4B-8A87-9EA5C87FF410Q33692259-5CFAAEFA-924D-48BF-9E9C-B46E3C5289AFQ34038203-44FBB084-6208-40EA-BEB2-A0D4F81BB691Q34045509-A511EE3F-61C2-43BF-9AEC-04928C9967B9Q34124421-6B54E0B9-FF7A-4AC7-A7CB-5CF852264B96Q34231151-0652270F-4366-4279-AF4E-40761B1E17B5Q34787422-E8CC61F2-410B-4ED9-8279-772730932317Q35216052-57170E41-F6A6-4DEF-A5AA-662311B5859EQ35234339-5823A3CD-2D5A-414A-872D-5CBA7D6204AEQ35830913-D5A5DF58-BF8A-486E-86B8-61073F97A8C9Q35832669-90F09D81-8779-4A5B-BC88-034E75D7DAB8Q35976186-DCDA5820-0D58-443E-B890-AAFE759CEF3AQ36116240-F64FD8A6-D5D9-4423-8A08-858C2A6EBE53Q36116250-C0A1C144-52C3-4281-9869-5810F7923EF1Q36135626-290A5A91-4C17-44FA-A68C-346560E0571BQ36136019-689FC223-94A7-4E66-A7B7-C9DA90B3863CQ36136193-94394435-E7B1-441E-9FFF-2A75653D971AQ36232599-84275856-5C50-44B6-8517-0B7B1ACAAB82Q36253648-8BCF5C51-2C9E-4A23-BA3A-92BE464183ECQ36292265-6FBEA848-0A6D-48F8-A92D-9CC8EECBB3ACQ36423492-F066895C-86B6-497E-92A1-B8885BB988FCQ36565186-864A14A6-7DB5-44D0-B4F3-D08687709C5DQ36622264-B2C4037D-A044-4908-8578-82710BF0AE08Q36623274-915784E3-04C0-4642-B0DE-8436E29EA484Q36642239-70C85FC7-1455-4224-B9B1-26E34A938F84Q36644476-4406D02E-BCC9-4C35-9FA9-C9F717E817AEQ36644659-BC222155-822C-4999-99BE-0B12DAD8EBBCQ36833642-2B200178-EF6E-4451-95C3-46D54C588734Q36893092-83D27241-B74E-48FB-9685-C5FB89E6F033Q37148681-2D315847-DA38-46AA-9FE7-06871ABBBD16Q37326072-B929EC5F-CE32-46C7-B4FF-0AFB0685F45BQ37529089-2E82128B-4AEF-4F75-8197-F3ED19A193ABQ37587395-E85054BD-2E7B-4B61-875D-4F544420E777Q37598840-80D7BA05-26B5-4282-BA94-70852CC94ABCQ37624379-4E2EBFEA-9D2B-4B94-AF51-F9E48209DE54Q38000790-0873962C-3D86-4B76-8BD2-87CEB773FB6AQ38295085-A22F4686-B4D4-4584-8A33-B86B06612932Q38673589-601F106B-56A5-462A-B81C-7565BD8A1010
P2860
p185neu expression in human lung adenocarcinomas predicts shortened survival.
description
1990 nî lūn-bûn
@nan
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
1990年论文
@zh
1990年论文
@zh-cn
name
p185neu expression in human lung adenocarcinomas predicts shortened survival.
@en
type
label
p185neu expression in human lung adenocarcinomas predicts shortened survival.
@en
prefLabel
p185neu expression in human lung adenocarcinomas predicts shortened survival.
@en
P2093
P1433
P1476
p185neu expression in human lung adenocarcinomas predicts shortened survival.
@en
P2093
Nordberg JE
Robinson RA
Schwartz DA
P304
P407
P577
1990-08-01T00:00:00Z